ClinicalTrials.Veeva

Menu

A Study To Estimate The Relative Bioavailability Of PF-00258210 Administered Alone Or In Combination With PF-00610355

Pfizer logo

Pfizer

Status and phase

Completed
Phase 1

Conditions

Asthma

Treatments

Drug: Treatment D
Drug: Treatment A
Drug: Treatment C
Drug: Treatment B
Drug: Treatment E

Study type

Interventional

Funder types

Industry

Identifiers

NCT01043276
B0751001

Details and patient eligibility

About

The purpose of this study if to investiagte the time course of PF-00258210 plasma concentration in the presence or absence of PF-00610335 administered via oral inhalation using dry powder inhalers

Enrollment

20 patients

Sex

All

Ages

18 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy male and/or female subjects between the ages of 21 and 55 years, inclusive

Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs)

Exclusion criteria

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)
  • A positive urine drug screen
  • Pregnant or nursing females

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

20 participants in 5 patient groups

Treatment A
Experimental group
Treatment:
Drug: Treatment A
Treatment B
Experimental group
Treatment:
Drug: Treatment B
Treatment C
Experimental group
Treatment:
Drug: Treatment C
Treatment D
Experimental group
Treatment:
Drug: Treatment D
Treatment E
Experimental group
Treatment:
Drug: Treatment E

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems